Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs

Ashish Sharma; Nilesh Kumar; Nikulaa Parachuri; Francesco Bandello; Anat Loewenstein; Baruch D. Kuppermann

doi:10.1038/s41433-024-03001-8

Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs

Ashish Sharma^*, Nilesh Kumar, Nikulaa Parachuri, Francesco Bandello, Anat Loewenstein, Baruch D. Kuppermann

^*Corresponding author for this work

Ophthalmology

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	1796-1798
Number of pages	3
Journal	Eye (Basingstoke)
Volume	38
Issue number	10
DOIs	https://doi.org/10.1038/s41433-024-03001-8
State	Published - Jul 2024

Access to Document

10.1038/s41433-024-03001-8

Cite this

@article{9ef1628e6fba40b58a445bd55f92418c,

title = "Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs",

author = "Ashish Sharma and Nilesh Kumar and Nikulaa Parachuri and Francesco Bandello and Anat Loewenstein and Kuppermann, {Baruch D.}",

year = "2024",

month = jul,

doi = "10.1038/s41433-024-03001-8",

language = "אנגלית",

volume = "38",

pages = "1796--1798",

journal = "Eye (Basingstoke)",

issn = "0950-222X",

publisher = "Springer Nature",

number = "10",

}

TY - JOUR

T1 - Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs

AU - Sharma, Ashish

AU - Kumar, Nilesh

AU - Parachuri, Nikulaa

AU - Bandello, Francesco

AU - Loewenstein, Anat

AU - Kuppermann, Baruch D.

PY - 2024/7

Y1 - 2024/7

UR - http://www.scopus.com/inward/record.url?scp=85186542405&partnerID=8YFLogxK

U2 - 10.1038/s41433-024-03001-8

DO - 10.1038/s41433-024-03001-8

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 38438797

AN - SCOPUS:85186542405

SN - 0950-222X

VL - 38

SP - 1796

EP - 1798

JO - Eye (Basingstoke)

JF - Eye (Basingstoke)

IS - 10

ER -

Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs

Access to Document

Other files and links

Cite this